Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2011

View Archived Issues

Sunnybrook Health Sciences and sanofi-aventis to develop vasculotide

AR-42 displays potent antitumor effects in models of embryonal carcinoma

BMS-936558 shows promise in RCC and mCRPC in phase I trial

Combined GWAS meta-analysis reveals shared genetic risk loci for Crohn's disease and celiac disease

Epidermal growth factor receptor may be marker of progression of penile squamous cancer

CD151 antigen is a marker of prostate cancer recurrence after radical prostatectomy

Vertex reports clinical data on ivacaftor in cystic fibrosis

Enrollment complete in translational clinical study of Reolysin in metastatic colorectal cancer

Bayer and Onyx begin enrollment in phase III Nexavar trial in advanced breast cancer

Evolva demonstrates preclinical efficacy of EV-077 in influenza

FDA approves OraQuick HCV Rapid Antibody Test

Endpoints met in phase Ib trial of TransPharma's ViaDor-GLP-1 agonist in type 2 diabetes

Novo Nordisk submits BLA to FDA for rFXIII in FXIII deficiency

FDA approves label update for Onglyza

NPS Pharma gives product pipeline update

IRM discloses new inhibitors of tyrosine-protein kinase SYK

Merck & Co. discloses new inhibitors of HCV serine protease NS3

Takeda submits NDA to FDA for azilsartan medoxomil plus chlorthalidone

Pharmaxis launches Aridol test kit in U.S. for bronchial hyperresponsiveness

Novartis claims new inhibitors of cyclin-dependent kinase 9

NV Organon patents new glycoprotein hormone FSH receptor agonists

Salix provides update on Xifaxan sNDA for non-constipation-predominant IBS and IBS-related bloating

Ascendis Pharma divulges new prodrugs of pramipexole

Trevena begins phase II TRV-120027 trial in acute heart failure

Isis reports phase I data on C-reactive protein inhibitor ISIS-CRPRx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...